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Abstract
Background: The performance of routine and supplemental immunization activities is usually measured by the
administrative method: dividing the number of doses distributed by the size of the target population. This method leads to
coverage estimates that are sometimes impossible (e.g., vaccination of 102% of the target population), and are generally
inconsistent with the proportion found to be vaccinated in Demographic and Health Surveys (DHS). We describe a method
that estimates the fraction of the population accessible to vaccination activities, as well as within-campaign inefficiencies,
thus providing a consistent estimate of vaccination coverage.
Methods and Findings: We developed a likelihood framework for estimating the effective coverage of vaccination
programs using cross-sectional surveys of vaccine coverage combined with administrative data. We applied our method to
measles vaccination in three African countries: Ghana, Madagascar, and Sierra Leone, using data from each country’s most
recent DHS survey and administrative coverage data reported to the World Health Organization. We estimate that 93% (95%
CI: 91, 94) of the population in Ghana was ever covered by any measles vaccination activity, 77% (95% CI: 78, 81) in
Madagascar, and 69% (95% CI: 67, 70) in Sierra Leone. ‘‘Within-activity’’ inefficiencies were estimated to be low in Ghana,
and higher in Sierra Leone and Madagascar. Our model successfully fits age-specific vaccination coverage levels seen in DHS
data, which differ markedly from those predicted by naı ¨ve extrapolation from country-reported and World Health
Organization–adjusted vaccination coverage.
Conclusions: Combining administrative data with survey data substantially improves estimates of vaccination coverage.
Estimates of the inefficiency of past vaccination activities and the proportion not covered by any activity allow us to more
accurately predict the results of future activities and provide insight into the ways in which vaccination programs are failing
to meet their goals.
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Immunization is a proven and cost-effective tool for control of
infectious disease. Two main types of immunization activities are
used to deliver vaccinations to populations, routine immunization
and mass campaigns such as Supplemental Immunization Activities
(SIAs). Routine immunization occurs year-round, with the aim of
providing coverage for all children, as part of the World Health
Organization (WHO) Expanded Program on Immunization. In
contexts whereimmunization goalsarenotmet byroutine activities,
such as measles vaccination in sub-Saharan Africa, SIAs are used to
increase vaccination coverage and provide the opportunity for a
second dose of vaccine. SIAs occur via campaigns at intervals
generally greater than 2 y, targeting a broader range of ages.
Throughout this paper, we use the term ‘‘immunization activities’’
to refer to both types of vaccination efforts, and specifically refer to
the former as ‘‘routine vaccination’’ and the latter as ‘‘campaigns.’’
Establishing coverage attained via these immunization activities
(i.e., routine coverage and campaigns) is of clear programmatic
importance. The coverage of vaccination activities is usually
determined by comparing the number of doses distributed during
the activity by the size of the target population (the administrative
method) [1]. This calculation ignores vaccine wastage and failure
to vaccinate inaccessible populations [2], and can sometimes lead
to nonsensical results such as ‘‘we vaccinated 120% of children
from 9 to 48 months of age’’ [1]. A more direct approach to
assessing the success of a vaccination activity is to quantify
outcomes (i.e., degree of coverage attained), rather than inputs
(i.e., number of vaccines distributed). One measure of outcomes is
provided by Demographic and Health Surveys (DHS), nationally
representative household surveys undertaken globally and geared
to provide comparable data for a wide range of monitoring and
impact evaluation indicators for population health, including
immunization status [3].
Considering vaccination outcomes (e.g., age-specific vaccination
rates) yields more accurate measures of coverage [2], and may also
allow identification of key correlates of vaccination (e.g., rural
versus urban) [4]. However, considering outcomes alone cannot
reveal whether poor coverage is predominantly due to a
proportion of the population being inaccessible to vaccination,
or predominantly due to distribution inefficiencies and wastage
within campaigns and routine activities. Here we show how linking
the input information (doses distributed) to the outcomes (age-
specific vaccination coverage) allows us to quantify the relative
importance of these two components, improving our operational
understanding of vaccination activities.
The ‘‘inaccessible population’’ includes those who refuse
vaccination (perhaps accounting for the majority of the ‘‘unreach-
able’’ group in highly developed nations [5]) and those who do not
have physical access to vaccination, e.g., people living in remote
areas with little access to health care services [6]. In addition to
groups who are literally inaccessible, the inaccessible population
includes individuals not covered because of overlaps between
vaccination activities larger than would be expected by chance
alone (i.e., correlations in coverage). For example, overlaps may
occur if vaccination activities tend to reach some sub-populations
more effectively than others. Hence, while particular immuniza-
tion activities may have covered more or less of the accessible
population, the size of the accessible population represents an
upper limit on both the coverage attained by any particular
activity and the coverage of all activities combined.
Individuals who are, in theory, targeted and reachable by
vaccination activities may also be missed because of inefficiencies
within immunization activities, such that not all nominally
distributed doses (i.e., doses reported as distributed on country
reports) result in an actual new vaccinee. Vaccine wastage may
result from discarded doses (due to cold chain lapses or partial use
of open vials), vaccination of individuals outside the target
population, or revaccination of children already vaccinated within
that activity [7]. Note that we consider revaccination an
inefficiency only if a child receives two doses in the same activity
(e.g., within the same campaign), not if they are vaccinated
multiple times in separate activities (e.g., receiving one routine
dose and one campaign dose), which may often be desirable.
These within-activity inefficiencies dictate how many new
vaccinees will be gained for each new dose of vaccine added to
a single vaccination activity.
Here we introduce a likelihood formulation that can be used to
estimate both the size of the population inaccessible to vaccination
activities and the inefficiency in the distribution of vaccine within
activities. Taken together, these two quantities dictate both the
rate and upper limit of improvement achievable solely by
introducing new doses of vaccine into a health system. The
analysis provides a method to predict the performance of past
vaccination activities and future activities if no systematic changes
are made. Also, it may provide some insight into where the vaccine
distribution system is failing (e.g., is there a large inaccessible
population, or are large numbers of doses being wasted within
activities?). Our framework requires only data from a cross-
sectional survey measuring age and vaccination status, and
information on vaccination activity timing, age range, and number
of doses deployed in the years preceding the survey. We illustrate
our technique using publicly available data on measles vaccination
in Ghana, Madagascar, and Sierra Leone.
Methods
Estimating Effective Vaccine Coverage
Data requirements. Two sources of data are needed to
estimate effective vaccine coverage using our method. The first is
administrative data on vaccination activities conducted during the
period of interest, including both campaigns and routine
vaccination. For each vaccination activity we need to know
when the activity occurred, the target age range for the activity,
the number of vaccine doses nominally distributed, and the size of
the target population. Routine vaccination activities occur over a
broad time frame, hence must be treated differently than
campaigns in statistical procedures (see ‘‘Modeling Routine
Vaccination’’ below). However, from a data standpoint, each
year’s routine vaccination activities can be represented as a
pseudo-campaign occurring on January 1 of that year covering all
ages. The first four columns of Table 1 illustrate the data on
vaccination activities required by our approach.
The second type of data required is a cross-sectional survey of
age and vaccination status in the population. This survey may be
an age-stratified survey aimed specifically at this question, or any
cross-sectional survey where the vaccination status of children of
differing ages is obtained (e.g., a DHS survey). Data from
vaccination cards, indicating a child’s age at the time of routine
vaccination, are not necessary but can be used to improve
estimates of the age distribution of routine coverage.
Vaccination probability and coverage. Suppose that an
individual has been in the target population for vaccination
activities V1, V2,…, Vm. The probability that this individual has
been vaccinated is one minus the probability that they avoid
vaccination in every activity:
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...|Pr not vaccinated inVm ðÞ
ð1Þ
Let us assume that there exists some population of size 12r that
never has a chance of being vaccinated in any activity, which we
term the inaccessible population. The probability that an
individual is vaccinated is then:
1 { 1 {r ðÞ zrP
m
j~1
Pr not vaccinated inVjjin accessible population
  
  
ð2Þ
The probability that an individual in the accessible population is
vaccinated during activity Vj is some function of the number of
vaccine doses nominally distributed during that activity, vj, the size
of the population targeted by that activity, Nj, and the proportion
of that targeted population that is accessible to vaccination
activities in general, r. If vaccine doses were distributed with
perfect efficiency, then this value would be vj/rNj. However, it
seems reasonable to assume that there is some inefficiency in the
distribution of vaccine to the accessible target population, and that
this inefficiency has a larger effect as more nominal vaccinations
occur during an activity. That is, the first nominally distributed
dose will nearly assuredly result in an additional vaccinee, but the
1,000th nominally distributed dose has a smaller chance of
resulting in an additional vaccinee, and the 100,000th nominally
distributed dose has a still smaller chance. We denote this
inefficiency y, where y=0 denotes an activity with perfect
efficiency, i.e., every dose results in an additional vaccinee, and
y=1denotes a campaign that is effectively at random, i.e., your
chance of receiving any vaccine dose is independent of your
chance of receiving a dose previously in that activity (though
unlikely, values of y.1 are possible, and represent activities worse
than at random). Hence, the probability of an individual in the
accessible target population remaining unvaccinated during
activity Vj is f(vj, rNj, y) where (see Text S1 for derivation):
1{f nj,rNj,y
  
~
e
{nj
 
rNj if y~1
1{
nj
rNj
1{y ðÞ
   1= 1{y ðÞ
otherwise
8
> > <
> > :
ð3Þ
Table 1. Timing, administrative coverage, and estimated coverage of routine and supplemental vaccination activities for Ghana,
Madagascar, and Sierra Leone.
Date Type Doses, V
Target
Population, N
Administrative
Coverage (100V/N)
WHO Estimated
Coverage
Model Estimated
Coverage (95% CI)
Ghana
2003 Routine 646,166 775,191 83% 80% 82% (81, 82)
2004 Routine 660,776 793,461 83% 83% 82% (81, 82)
2005 Routine 718,589 812,221 88% 83% 87% (85, 87)
2006 (Nov 1) SIA, children aged 9–60 mo 3,994,052 5,065,661 79% — 77% (77, 78)
2006 Routine 759,222 891,586 85% 85% 83% (82, 84)
2007 Routine 812,083 857,899 95% 95% 92% (91, 93)
2008 Routine 815,617 882,953 92% 86% 90% (89, 91)
Madagascar
2003 Routine 500,960 583,339 86% 56% 67% (65, 69)
2004 Routine 590,167 601,428 98% 58% 72% (70, 75)
2004 (Sep 13) SIA, children aged 9–168 mo 7,546,229 7,626,090 99% — 73% (70, 75)
2005 Routine 499,119 595,349 84% 61% 66% (64, 68)
2006 Routine 513,868 612,018 84% 65% 66% (64, 68)
2007 Routine 614,825 629,154 98% 81% 72% (70, 74)
2007 (Oct 22) SIA, children aged 9–60 mo 3,053,702 3,123,163 98% — 72% (70, 74)
2008 Routine 620,985 682,680 91% 70% 69% (67, 71)
2009 Routine 595,514 701,795 85% 64% 66% (64, 68)
Sierra Leone
2003 Routine 160,094 185,150 86% 73% 64% (62, 66)
2003 (Oct 28) SIA, children aged 9–168 mo 2,404,882 2,599,098 93% — 66% (64, 68)
2004 Routine 139,571 217,438 64% 76% 53% (51, 54)
2005 Routine 153,184 190,143 81% 71% 62% (60, 63)
2006 (Nov 26) SIA, children aged 9–60 mo 796,509 792,401 101% — 68% (66, 70)
2006 Routine 155,408 171,908 90% 65% 66% (64, 67)
2007 Routine 155,933 189,149 82% 60% 63% (61, 64)
2008 Routine 190,048 198,251 96% 66% 67% (65, 69)
doi:10.1371/journal.pmed.1001110.t001
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expression of the probability that any individual i has been
vaccinated:
gx i;r, y ðÞ ~r 1{ P
m
j~1
f nj,rNj, y
      zij
  
ð4Þ
Where V1, V2,…, Vm now denotes all vaccination activities that
anyone in the population has been exposed to, and zij is an
indicator of whether person i was in the target population for
vaccine activity j, which is fully determined by the child’s age (xi).
The coverage of a particular vaccination activity, cj, is the same
as the probability that an individual who is in the target population
for only that activity (i.e., zij=1 and zik=0 for all k?j)i s
vaccinated. Hence, the expected coverage of activity j is:
cj~r 1{f(vj,rNj,y)
  
ð5Þ
Figures 1 and 2 illustrate how r and y affect actual coverage.
The accessible population, r, represents the upper limit of
coverage, while the efficiency parameter, y, dictates the expected
improvement in coverage from the introduction of additional
vaccine doses.
Modeling routine vaccination. In the simplest formulation,
routine vaccination activities can be treated as a single pseudo-
campaign occurring when a child reaches the age of
recommended vaccination (9 mo for measles), with the routine
vaccination coverage reported during the year of that event.
However, this approach ignores the fact that different children
receive their first dose of vaccine from routine immunization
activities at different ages. We can account for this by creating a
series of pseudo-campaigns representing the routine vaccination
coverage of each year when child i was alive. By weighting each
pseudo-campaign by the probability of a child having the
‘‘opportunity’’ to be vaccinated in a year’s routine activities (wij),
these pseudo-campaigns can be combined to obtain a child’s
probability of routine vaccination in their lifetime up to that point
(see Text S1):
fR xi, v,r N,y ðÞ ~w 
i z
X R
j~1
wijf(vj,rNj,y) ð6Þ
where j=1…R are the years of routine vaccination activities and
w 
i represents the probability that the opportunity for routine
vaccination occurs after a child’s current age. These weights are
calculated as (see Text S1):
wij~FR xijzlj
  
{FR xij
  
ð7Þ
w 
i ~1{F(xi) ð8Þ
where FR(x) is the probability of having the opportunity for
vaccination by age x, xij is child i’s age at the beginning of routine
vaccination year j, and lj is the length of exposure to a year’s
routine activities (12 mo for most years, but truncated in the year
of the survey). This new combination of pseudo-campaigns can be
included in Equation 4 above as a single vaccination activity.
Sophisticated distributions and forms of estimation for FR(x) are
possible, but here we make the simplifying assumption that there is
a constant ‘‘hazard’’ l of routine vaccination after 8.5 mo of age
and estimate this hazard in conjunction with the other model
parameters. That is:
FR x ðÞ ~
0i f xv8:5mo
1{e{l x{8:5 ðÞ otherwise
 
ð9Þ
Estimation. In a cross-sectional survey we observe a set of
individuals with ages x={x1, x2,…, xn} and a set of corresponding
vaccination statuses, y={y1, y2,…, yn}, where yi=0 indicates that
an individual has never been vaccinated, and yi=1 indicates that
he has. Using the formulation from Equation 4, the probability of
observing yi=1isg(xi, r, y), and the probability of observing yi=0
is 12g(xi, r, y). Assuming that y1, y2,…, yn are independent
stochastic variables, the likelihood of the parameters r and y given
these observations can be expressed as the product of the
probability of each observation:
L r,y,l;x,y ðÞ ~ P
n
i~1
gx i;r,y,l ðÞ
yi 1{gx i;r,y,l ðÞ ðÞ
1{yi ð10Þ
Numeric optimization (e.g., Nelder-Mead) or Markov chain
Monte Carlo (MCMC) methods can be used to estimate these
parameters.
We extend Equation 10 to use data on the age at time of
vaccination for those with vaccine cards to better fit l, optimizing:
L r,y,l;x,y ðÞ ~ P
n
i~1
gx i;r,y,l ðÞ
yi 1 {gx i;r,y,l ðÞ ðÞ
1 {yi
  
P
n’
i~ 1
hr i,l ðÞ
  
ð11Þ
where n9 is the number of children with a vaccination card, ri is the
age of routine vaccination on that card, and h(ri, l) is the
probability distribution function for Equation 9. This formulation
assumes that the age of routine vaccination is independent of the
probability of vaccination given that a child has a vaccination card
doses delivered per 100 population
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Figure 1. Expected coverage of a vaccination activity based on
the values of y and r. The left y-axis presents the proportion of the
total target population, while the right y-axis shows the proportion
vaccinated as a proportion of the accessible population, r. A value of
y=0 indicates ‘‘perfect’’ vaccine distribution, where every dose of
vaccine reaches an individual not yet vaccinated in this activity, y=1
indicates vaccine distribution equivalent to ‘‘vaccination at random,’’
and values of y greater than one indicate even worse performance.
doi:10.1371/journal.pmed.1001110.g001
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represent routine vaccination.
Application to Measles Vaccination
We used data from WHO and country DHS to estimate the
effectiveness of measles vaccination activities in Ghana, Madagas-
car, and Sierra Leone. Countries were selected with the criteria that
at least one campaign (i.e., an SIA) occurred within the 5 y prior to
the most recent DHS survey, that no campaign occurred in the
same year as the most recent DHS survey, and that countries with
differing reported vaccination coverage were represented.
Values for the number of doses nominally administered during
routine vaccination and the size of the target population are based
on the values reported by countries to WHO (data provided by
WHO). WHO–United Nations Children’s Fund (UNICEF)
estimates of national immunization coverage for comparison were
obtained from WHO [8]. Information on when campaigns
occurred, doses deployed during campaigns, and the age range
targeted were obtained from WHO.
Measles vaccination status for children from 9 to 59 mo of age
was obtained from country-specific DHS surveys [9–11]. Children
were considered to have been vaccinated for measles if vaccination
was recorded on the child’s health card or the child’s mother
reported that the child had been vaccinated (Table 2). Vaccination
status, age, and timing of interview were obtained for 2,304
children from Ghana (DHS survey in 2008), n=9,747 for
Madagascar (DHS survey in 2008–2009), and n=3,966 for Sierra
Leone (DHS survey in 2008). Age at time of routine vaccination
was calculated for those children where the DHS data indicated a
vaccination card had been seen and a date of vaccination was
recorded (n=1,550 for Ghana, 3,787 for Madagascar, and 1,216
for Sierra Leone).
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Figure 2. The expected number of additional people vaccinated in a vaccination activity per batch of 100 vaccine doses delivered,
in a hypothetical population of 1,000 individuals where r=0.8. If y=0, then each vaccine dose reaches an individual not yet covered by this
activity until the entire accessible population is vaccinated (800 individuals in this example). For higher values of y, each additional dose delivered
into the system has a reduced chance of reaching an individual not yet covered by this activity.
doi:10.1371/journal.pmed.1001110.g002
Table 2. Details of DHS data, contrasting numbers, and percent reported vaccinated by age as ascertained by vaccination cards, as
reported by mothers, and from either source.
Country Year Number Surveyed Vaccination Report Source Age
9–23 mo 24–35 mo 36–47 mo 48–60 mo
Ghana 2008 2,304 Card 529 (72%) 388 (76%) 307 (61%) 326 (58%)
Mother 70 (10%) 89 (18%) 136 (27%) 185 (33%)
Either 599 (82%) 477 (94%) 443 (88%) 511 (91%)
Total surveyed 734 508 501 561
Madagascar 2008–2009 9,747 Card 1,147 (42%) 984 (41%) 845 (38%) 811 (33%)
Mother 539 (20%) 815 (34%) 846 (38%) 1,037 (43%)
Either 1,686 (62%) 1,799 (76%) 1,691 (75%) 1,848 (77%)
Total surveyed 2,724 2,374 2,250 2,399
Sierra Leone 2008 3,966 Card 454 (35%) 322 (36%) 229 (25%) 211 (25%)
Mother 272 (21%) 286 (32%) 393 (42%) 366 (43%)
Either 726 (56%) 608 (68%) 622 (67%) 577 (68%)
Total surveyed 1,302 895 925 844
In some cases a card was present, but the date of vaccination was not recorded.
doi:10.1371/journal.pmed.1001110.t002
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obtained using MCMC methods (the Metropolis-Hasting algo-
rithm). All MCMC chains were started from r=0.5, y=1, and
l=1. Model convergence was checked by examination of MCMC
chains, comparison of the posterior distributions estimated from
different chains, calculation of ^ R R [12], and comparison with results
from numerical fitting procedures (Nelder-Mead). Five chains of
length 5,000 were run for each country, and the posterior
distribution was estimated to be the empirical distribution of the
combined set of the last 2,500 iterations from all chains. Reported
parameter estimates are the medians of the posterior distributions
(posteriors were normally distributed on the scale used in
estimation), and 95% confidence intervals from quantiles of the
posterior distribution. The estimated coverage for each campaign
and confidence intervals were similarly obtained from the
posterior distribution created by applying Equation 5.
Confidence intervals on the age distribution of vaccination
reported in DHS data were obtained by bootstrapping (500
iterations). Confidence intervals for model estimates of the age
distribution of vaccination were obtained by performing 500
parametric bootstrap iterations where (a) parameters were sampled
from the posterior distribution, (b) a bootstrap population is
created based on the DHS data, and (c) each individual in the
bootstrap population is randomly assigned a vaccination status
based on the parameters selected in step a. This procedure
accounts for (a) uncertainty in parameter estimates, (b) uncertainty
in population structure, and (c) uncertainty from the Bernoulli
process; confidence intervals are thus comparable with those
obtained from the DHS data.
The age distribution that would have resulted from naı ¨ve use of
WHO-corrected estimates of coverage was calculated assuming
independence between vaccination activities and routine vaccina-
tion at 9 mo of age. Campaigns were assumed to have coverage
that differed from that reported by the same proportion as the
routine vaccination activities occurring that year. Confidence
intervals were calculated using steps b and c above.
All statistical analyses were done in the R statistical package,
version 2.11 (http://cran.r-project.org).
Results
We estimate that 7% (95% CI: 6, 9) of children in Ghana, 23%
(95% CI: 24, 22) of children in Madagascar, and 31% (95% CI:
33, 30) of children in Sierra Leone were never accessible by
routine measles vaccination or campaigns (Table 3). The
estimated inefficiency within vaccination activities was highest
in Madagascar (y=0.34, 95% CI: 0.28, 0.41), followed by Sierra
Leone (y=0.33, 95% CI: 0.31, 0.39), then Ghana (y=0.03,
95% CI: 0.02, 0.04). Hence, our estimates of routine and SIA
coverage are substantially lower than administrative estimates for
Madagascar and Sierra Leone, and only slightly lower for Ghana
(Table 1). Our estimates of routine coverage are in general lower
than the WHO-UNICEF estimates generated by a heuristic
method.
Based on our estimated routine vaccination distribution (l;
Table 3), children in all three countries who receive routine
vaccination do so near their 9-mo birthday. In Ghana, children
receive routine vaccination at a slightly younger age (mean
age=10.0 mo) than in Madagascar (mean age=10.2 mo) or
Sierra Leone (mean age=10.6 mo). These estimates are slightly
lower than estimates obtained from the empirical distribution of
ages reported on vaccination cards (mean=10.4, 10.8, and
12.2 mo respectively), reflecting that the constant rate assumption
is not precisely correct.
A comparison of the age-specific proportion vaccinated predicted
by our approach with the proportion vaccinated observed in the
DHS data shows substantial agreement (Figure 3). For Madagascar
and Sierra Leone, our predictions show substantially better
agreement with the DHS data than what is predicted by naı ¨ve
application of WHO-adjusted coverage estimates. For Ghana,
where vaccination coverage is relatively high, the unreachable
population is small, and wastage very low, projections from WHO
generally agree with our estimates and the proportion vaccinated
observed in the DHS.
With the exception of Ghana, we find that the models including
both r and y as free parameters model the data substantially
better, as measured by Akaike information criterion, than models
where we assume a fully accessible population (r=1) or perfect
efficiency (y=0) (Table S1). In the case of Ghana, where y is
estimated to be nearly zero, assuming perfect efficiency leads to a
slightly improved but qualitatively equivalent model of the DHS
data.
Discussion
Reliable estimates of vaccination coverage are key to managing
population immunization status. Estimates of coverage are usually
based on administrative measures (i.e., the ratio of distributed
doses to the size of the target population). Refinements of this
approach do exist; however, current WHO adjustments of
estimates of coverage employ a heuristic method in which ‘‘no
statistical or mathematical models are used.’’ [1]. Data quality
audits [13] provide a verification factor that as yet has not proved
sufficiently stable to be useful [14]. Here we have introduced a
method by which administrative coverage estimates can be
combined with a cross-sectional survey to estimate the effective-
ness of vaccination programs. This method not only attempts to
correct coverage estimates, but also distinguishes between issues of
overall coverage and vaccine wastage within vaccination activities.
The causes of variation between country-specific levels of
inefficiency and overlap between campaigns (Table 3) may be
diverse, but general conclusions about immunization activities
emerge. While a combination of routine immunization via the
WHO Expanded Program on Immunization and campaigns can
Table 3. Estimated proportion of the population accessible by any vaccination activity (r), within-activity inefficiency (y), and
routine vaccination opportunity rate (l) for Ghana, Madagascar, and Sierra Leone.
Country ry l
Ghana 93% (95% CI: 91, 94) 0.03 (95% CI: 0.02, 0.04) 0.66 (95% CI: 0.54, 0.82)
Madagascar 77% (95% CI: 76, 78) 0.34 (95% CI: 0.28, 0.41) 0.60 (95% CI: 0.49, 0.73)
Sierra Leone 69% (95% CI: 67, 70) 0.33 (95% CI: 0.31, 0.39) 0.47 (95% CI: 0.38, 0.61)
doi:10.1371/journal.pmed.1001110.t003
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analysis shows how in contexts like that of post-conflict Sierra
Leone, or Madagascar, the strategy itself may be inadequate. For
example, in Sierra Leone, despite investment in two campaigns in
3 y, both these campaigns and the underlying routine program
failed to reach 30% of children; and in 2010, there was a large
outbreak in children aged greater than 5 y in Freetown. More
generally, wherever such a large proportion of the population
remains inaccessible, e.g., when there is high overlap between
campaigns, the combined strategy of vaccination via the Expanded
Program on Immunization and via SIAs is unlikely to succeed, and
refocusing effort into the design of vaccination strategy (e.g.,
improving the vaccine distribution structure and finding novel
ways to target unreached populations) should yield considerable
rewards in terms of improved coverage.
For our technique to be useful, countries must have cross-
sectional data on vaccine coverage for children across a range of
ages, some of an age where they have been exposed to multiple
vaccination activities (e.g., one or more campaigns and routine
vaccination). As illustrated here, a DHS survey provides sufficient
information, but surveys aimed specifically at measuring coverage
that target a wider age range (ideally paired with serosurveys)
could improve estimates. Once countries have estimates of the
accessible population and within-campaign inefficiencies, they can
predict the coverage of activities occurring after the cross-sectional
survey (using Equation 5) and the age-specific coverage obtained
after these activities (using Equation 4). With these estimates in
hand, countries can better understand how susceptibility may be
building up in their population, perhaps enabling them to avoid
outbreaks of the type and scale observed recently in Sierra Leone,
Malawi, Zambia, and South Africa.
It may seem surprising that both y and r are identifiable using
only age-stratified vaccination prevalence. However, simulations
show that differences in these values lead to significant differences
in the age profile of vaccination coverage when children of
differing ages have differing exposure to multiple vaccination
activities (Figures S1 and S2). If children are not exposed to
multiple activities (e.g., there is only routine vaccination), it will not
necessarily be possible to distinguish between these two sources of
program inefficiency. A critical way estimates could be improved is
by conducting cross-sectional surveys of vaccination coverage
covering ages greater than 5 y (the current upper limit in DHS
surveys). Such surveys would include individuals who had been
potentially covered by more vaccination campaigns, improving
estimates and allowing for separate analysis of inefficiencies in
routine vaccination and SIAs.
Limitations of our approach include required assumptions that
may not always be justified. The assumption of constant
inefficiencies across the study period may not be appropriate,
especially in the context of a global measles elimination campaign.
A potential extension to account for this variation would be to
allow estimates of r and y to vary smoothly over time. The
assumption that the rate at which children have the opportunity to
receive routine vaccination is constant after 8.5 mo of age is
clearly an oversimplification. While more sophisticated techniques
can be used to fit this age distribution, as in [15], the simplified
approach still fits the age distribution seen in the DHS data well
(Figure 3).
Our sample estimates are also subject to the quality of the
available data. We assume that the target population is accurately
estimated. A sensitivity analysis of the effect of over- or
underestimates of the target population indicates that such
misspecifications do not much bias estimates of the size of the
unreachable population, but do impact estimates of within-
campaign efficiency (Table S2). Underestimates of the size of the
target population lead to underestimates of within-campaign
efficiency (i.e., overestimates of y), and overestimates lead to
overestimates of within-campaign efficiency (i.e., underestimates of
y). Hence, the high within-campaign inefficiency estimates for
Sierra Leone and Madagascar could be partially the result of
poorly specified denominators, particularly as in both cases at least
some of the immunization activities were performed long after the
last census (Table S3).
We also assume that the DHS data are representative of each
country. If DHS surveys in fact missed populations that were also
missed by immunization activities, the size of the population
inaccessible to vaccination would be underestimated. Another
potential source of bias is that a high proportion of the
vaccination data come from reporting by the mother (Table 2),
particularly in Sierra Leone. If mothers report more children
have been vaccinated than is in fact the case, both the size of the
accessible population and the efficiency of campaigns may be
overestimated, and the reverse if mothers report fewer children
vaccinated than there really are. Additionally, in all countries, the
proportion of reports from the mother increases with child age,
reflecting the fact that vaccination cards are more rarely
distributed during SIAs. This could lead to either over- or under-
reporting of vaccination occurring during SIAs. If underreporting
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Figure 3. DHS and model estimates of age-specific vaccination coverage. Proportion vaccinated by age in (A) Ghana, (B) Madagascar, and
(C) Sierra Leone. Points connected by solid lines are the window-smoothed (age 65 mo) estimates of vaccine coverage as measured by the most
recent DHS survey (blue), as predicted by naı ¨ve application of WHO coverage estimates (green), and as fit using our approach (red) in a population
with the same age distribution as the DHS data. Shaded regions represent 95% confidence intervals on the window-smoothed estimate calculated as
described in Methods.
doi:10.1371/journal.pmed.1001110.g003
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underestimate overall coverage and overestimate within-cam-
paign inefficiency. Conversely, if campaign coverage is overre-
ported, our technique will underestimate within-campaign
inefficiencies. Age-specific serosurveys would provide a valuable
benchmark by which to evaluate the coverage estimates, and
could perhaps be paired with existing research, monitoring, or
vaccination activities.
The estimates obtained by our method bear an inconsistent
relationship to the WHO-UNICEF adjusted estimates (Table 1).
In some places we estimate significantly lower coverage (e.g.,
Sierra Leone in 2004) and in others we estimate higher coverage
(e.g., Ghana in 2005). In all cases our estimates are the result of the
reported administrative coverage and the estimated model
parameters. Where we estimate a large accessible population
and low inefficiency, our estimates will be high relative to
administrative coverage; where we estimate a small accessible
population and high inefficiency, our estimates will be relatively
low. We assume model parameters are constant over the 5 y
considered, while the heuristics used in the WHO-UNICEF
estimates may capture specific short-term factors of which we are
unaware [1], and hence may be more accurate for individual
years. However, without further information, it is unclear how to
combine yearly WHO-UNICEF estimates to the get full age
distribution of vaccine coverage (assuming independence clearly
performs poorly; Figure 3). Since the assessment of coverage from
multiple activities is integral to our approach, our approach has
some clear advantages despite its limitations.
The method presented here provides a way in which the
performance of vaccination activities can be more accurately
measured (and can be extended to consider, e.g., the problem of
access to a second dose; Figure S3). As illustrated by our examples,
this approach can be used to produce estimates of effective vaccine
coverage that are more consistent with the proportion of the
population reporting vaccination than current approaches are.
These estimates go beyond mere measures of cross-sectional
coverage obtained directly from a DHS survey, characterizing the
performance of the activities leading to that coverage, and helping
to predict the effect of future vaccination activities. Our estimates
can be used to identify those countries where problems in vaccine
delivery may exist (e.g., Madagascar and Sierra Leone), thereby
providing important operational guidance as to how vaccine
coverage may be improved. Such guidance is essential if measles
control goals are to be met.
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Figure S1 Log likelihood surfaces for four parameter
combinations. This figure shows in each case the ‘‘true’’
parameter values (used in the simulation) as a black point and the
peak of the log likelihood surface as a red point. Surfaces are based
on simulated vaccine outcomes for populations of 4,000
individuals across an age range of 9 to 60 mo, with r values of
0.75 (corresponding to a large unreachable population) and 0.95 (a
small unreachable population) and y values of 9 (high vaccine
wastage) and 0 (high efficiency and low wastage). We assumed
three SIA campaigns, each occurring a year apart, targeting
children aged 9 to 60 mo, and with coverage of 0.65. For clarity,
we assumed no routine vaccination.
(TIF)
Figure S2 Proportion vaccinated over age for four
parameter combinations. This figure demonstrates the
benefits achievable by decreasing the size of the unreachable
population (i.e., increasing r) or decreasing wastage (i.e.,
decreasing y). The figure is based upon simulated vaccine
outcomes for 4,000 individuals (see Figure S1).
(TIF)
Figure S3 Probability of vaccination in multiple activ-
ities. The estimated probability of a child having received two or
more doses of measles vaccine by age in the entire population (red)
and the accessible population only (orange) in (A) Ghana, (B)
Madagascar, and (C) Sierra Leone. Estimates assume an
independent probability of receiving a vaccination in each
vaccination activity given that an individual is in the accessible
population. In population-based estimates (red) the probability of
being in the accessible population is considered to be r;i n
accessible population estimates this probability is considered to be
one. Confidence intervals are calculated as described in Methods.
(TIF)
Table S1 Comparison of model fits to DHS data using
the full model. This table compares the performance of the full
model to a model where the entire population is assumed to be
accessible (r=1) and to a model where campaigns are assumed to
have perfect efficiency (y=0). Maximum likelihood estimates of
parameters were determined using Nelder-Mead numeric optimi-
zation, and in some cases differ slightly (by less than .01) from
MCMC-based estimates in the main analysis.
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Table S2 The effect of misspecified target population
size. (A) Simulation results for the mean bias when estimating y
and r with correct and misspecified target population size. To
examine possible bias in the estimation procedure, as well as biases
resulting from misspecification of the denominator, we performed
500 simulations of a population of 4,000 individuals and estimated
y and r with the assumed target population size being 80%, 95%,
100%, 105%, and 120% of its true value. We assessed the mean
bias in estimates of y and r (Table S1). We found that estimates of
the size of the unreachable population (r) were only biased when
size of the target population was severely overestimated (120% of
its actual value). Estimates of y are more sensitive to the
specification of the denominator, with underestimates leading to
substantial underestimates of within-campaign efficiency (i.e.,
overestimates of y), and overestimates leading to overestimates
of within-campaign efficiency (i.e., underestimates of y). (B)
Campaign coverage biases in percentages corresponding to
parameter estimates reflecting mean biases from population
misspecification in (A).
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Table S3 SIAs and population census timing and
coverage. Details of SIAs (years, estimated target population,
and estimated doses delivered; from [8]) and data on date of last
population census previous to each campaign from [16].
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Background. Immunization (vaccination) is a proven, cost-
effective tool for controlling life-threatening infectious
diseases. It provides protection against infectious diseases
by priming the human immune system to respond quickly
and efficiently to bacteria, viruses, and other disease-causing
organisms (pathogens). Whenever the human body is
exposed to a pathogen, the immune system—a network of
cells, tissues, and organs—mounts an attack against the
foreign invader. Importantly, the immune system ‘‘learns’’
from the encounter, and the next time the body is exposed
to the same pathogen, the immune system responds much
faster to the threat. Immunization exposes the body to a very
small amount of a pathogen, thereby safely providing
protection against subsequent infection. More than two
billion deaths are averted every year through routine
childhood immunization and supplemental immunization
activities (mass vaccination campaigns designed to increase
vaccination coverage where immunization goals have not
been reached by routine vaccination). Indeed, these two
types of vaccination activities have eliminated smallpox from
the world and are close to doing the same for several other
infectious diseases.
Why Was This Study Done? To reduce deaths from
infectious diseases even further, it is important to know the
proportion of the population reached by vaccination
activities. At present, countries report vaccination coverage
to the World Health Organization (WHO) that is calculated by
dividing the number of vaccine doses delivered during the
activity by the size of the target population. However,
estimates arrived at through this ‘‘administrative method’’ do
not account for vaccine doses that were not actually
delivered, and can only reflect a single vaccination activity,
which prevents us from identifying populations that may be
systematically missed by all vaccination activities (for
example, children living in remote areas, or children whose
parents refuse vaccination). Moreover, estimates of coverage
obtained by the administrative method rarely agree with
estimates obtained through cross-sectional surveys such as
Demographic and Health Surveys (DHS), which are
household surveys of family circumstances and health
undertaken at a single time point. In this study, the
researchers developed a method for measuring the
performance of vaccination activities that estimates the
fraction of the population accessible to these activities and
within-activity inefficiencies. They then tested their method
by applying it to measles vaccination in three African
countries; before 1980, measles killed about 2.6 million
children worldwide every year, but vaccination activities
have reduced this death toll to about 164,000 per year.
What Did the Researchers Do and Find? The researchers
developed a set of formulae (a ‘‘likelihood framework’’) to
estimate the effective coverage of vaccination activities
using data on vaccine coverage from cross-sectional surveys
and administrative data. They then applied their method to
measles vaccination in Ghana, Madagascar, and Sierra Leone
using data obtained in each country’s most recent DHS
survey and administrative data reported to WHO. The
researchers estimate that 93%, 77%, and 65% of the target
populations in Ghana, Madagascar, and Sierra Leone,
respectively, were ever covered by any vaccination activity,
and that inefficiencies within vaccination activities were low
for Ghana, but higher for Madagascar and Sierra Leone.
Consequently, the researchers’ estimates of vaccination
activity coverage were substantially lower than the
administrative estimates for Madagascar and Sierra Leone
but only slightly lower than that for Ghana. Finally, the
researchers’ estimates of routine vaccination coverage were
generally lower than WHO-adjusted estimates but broadly
agreed with age-specific vaccination coverage levels from
DHS surveys.
What Do These Findings Mean? Although the accuracy
of the estimates provided by this likelihood framework
depends on the assumptions included in the framework and
the quality of the data fed into it, these findings show that,
by combining administrative data with survey data,
estimates of vaccine coverage can be substantially
improved. By providing estimates of both the inefficiency
of past vaccination activities and the proportion of the target
population inaccessible to any vaccination activity, this
method should help public health experts predict the
results of future activities and help them understand why
some vaccination programs fail to meet their goals.
Importantly, knowing both the size of the inaccessible
population and the inefficiency level of past programs makes
it possible to estimate the effect of providing additional
doses of vaccine on vaccination coverage. Finally, the
application of this new method might help individual
countries understand how susceptibility to specific
infectious diseases is building up in their population and
enable them to avoid outbreaks similar to the measles
outbreaks that have recently occurred in several African
countries.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001080.
N WHO provides information about immunization and
details of its Expanded Program on Immunization and its
Global Immunization Vision and Strategy; WHO Africa
provides details about measles immunization in Africa; a
photo story about mass measles vaccination in Co ˆte
d’Ivoire is available (some material in several languages)
N The UK National Health Service Choices website provides
information for members of the public about immuniza-
tion
N The Measles Initiative is a collaborative effort that aims to
reduce global measles mortality through mass vaccination
campaigns and by strengthening routine immunization; its
website includes information on measles and measles
vaccination, including photos and videos of vaccination
activities
N MedlinePlus provides links to additional resources about
immunization and about measles (in English and Spanish)
N The charity website Healthtalkonline has interviews with
UK parents about their experience of immunizing their
children
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